Clinical trial
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial
NCT03596450 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 13, 2018
- Completion date
- June 9, 2023
- Enrollment
- 1,278 (actual)
- Sites
- 181
Conditions
As the registry lists them; a condition with its own page is linked.